Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials

Figures & data

Figure 1 Selection process of RCTs included in the meta-analysis.

Abbreviations: CR, complete response; ICIs, immune checkpoint inhibitors; RCT, randomized controlled trial.

Table 1 Baseline characteristics of nine included trials

Study/year	Treatment line	Total	Treatment arms	Median age (years)	Median PFS (months)	Median OS (months)	CR	No. for analysis
Socinski et al^Citation33/2018	First line	800	Atezolizumab+bevacizumab+CT	63	8.3	19.2	13	353
			Bevacizumab+CT	63	6.8	14.7	4	331
Hellmann et al^Citation32/2018	First line	299	Nivolumab+ipilimumab	64	7.2	NR	5	139
			CT	64	5.5	NR	1	160
Gandhi et al^Citation16/2018	First line	616	Pembrolizumab+CT	65	9	NR	2	410
			CT	63.5	6.7	11.3	1	206
Rittmeyer et al^Citation29/2017	Second line	850	Atezolizumab	63	2.8	13.8	6	425
			Docetaxel	64	4	9.6	1	425
Govindan et al^Citation19/2017	First line	956	Ipilimumab+CT	64	5.6	13.4	1	388
			Placebo+CT	64	5.6	12.4	2	361
Reck et al^Citation31/2016	First line	305	Pembrolizumab	64.5	10.3	NR	NR	154
			CT	66	6	NR	NR	151
Langer et al^Citation31/2016	First line	123	Pembrolizumab+CT	62.5	13	NR	0	60
			CT	63.2	8.9	NR	0	63
Brahmer et al^Citation27/2015	Second line	272	Nivolumab	62	3.5	9.2	NR	135
			Docetaxel	64	2.8	6	NR	137
Borghaei et al^Citation18/2015	Second line	582	Nivolumab	61	2.3	12.2	4	292
			Docetaxel	64	4.2	9.4	1	290

Abbreviations: CR, complete response; CT, chemotherapy; NR, not reported; OS, overall survival; PFS, progression-free survival.

Figure 2 Subgroup analysis based on treatment line for RR of CR associated with ICIs vs CT.

Abbreviations: CR, complete response; CT, chemotherapy; ICI, immune checkpoint inhibitor; NA, not available.

Figure 3 Correlation between median OS and PFS in NSCLC patients who received ICIs.

Abbreviations: ICI, immune checkpoint inhibitor; NSCLC, non-small-cell lung cancer; OS, overall survival; PFS, progression-free survival.

Figure 4 Correlation between median OS and CR in NSCLC patients who received ICIs.

Abbreviations: CR, complete response; ICI, immune checkpoint inhibitor; NSCLC, non-small-cell lung cancer; OS, overall survival.

Figure 5 Correlation between median OS and ORR in NSCLC patients who received ICIs.

Abbreviations: ICI, immune checkpoint inhibitor; NSCLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival.

SocinskiMAJotteRMCappuzzoFIMpower150 Study GroupAtezolizumab for first-line treatment of metastatic nonsquamous NSCLCN Engl J Med2018378242288230129863955

 PubMed Web of Science ®Google Scholar

HellmannMDCiuleanuTEPluzanskiANivolumab plus ipilimumab in lung cancer with a high tumor mutational burdenN Engl J Med2018378222093210429658845

 PubMed Web of Science ®Google Scholar

GandhiLRodríguez-AbreuDGadgeelSKEYNOTE-189 InvestigatorsPembrolizumab plus chemotherapy in metastatic non-small-cell lung cancerN Engl J Med2018378222078209229658856

 PubMed Web of Science ®Google Scholar

RittmeyerABarlesiFWaterkampDAtezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet20173891006625526527979383

 PubMed Web of Science ®Google Scholar

GovindanRSzczesnaAAhnMJPhase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancerJ Clin Oncol201735303449345728854067

 PubMed Web of Science ®Google Scholar

ReckMRodríguez-AbreuDRobinsonAGPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerN Engl J Med2016375191823183327718847

 PubMed Web of Science ®Google Scholar

BrahmerJReckampKLBaasPNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerN Engl J Med201537312313526028407

 PubMed Web of Science ®Google Scholar

BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med20153731627163926412456

 PubMed Web of Science ®Google Scholar